US Pharma MarketingThe post MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial appeared first on Clinical Trials Arena.
MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial
MSD acquired the anti-TL1A mAb tulisokibart in 2023 through its buyout of Prometheus Therapeutics for $10.8bn. MSD acquired tulisokibart in 2023 through its buyout of Prometheus Therapeutics. MSD is also investigating tulisokibart in Crohn’s disease, psoriatic arthritis and rheumatoid arthritis. Credit: HJBC / iStock Editorial via Getty Images MSD’s investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), which it acquired during a $10.8bn buyout of Prometheus Therapeutics, has met all its primary and secondary endpoints in a Phase III trial. In the ATLAS-UC induction-only study (NCT06052059), tulisokibart showed significant improvements in patients with moderately to severely active…
MSD acquired the anti-TL1A mAb tulisokibart in 2023 through its buyout of Prometheus Therapeutics for $10.8bn.
Source: Clinical Trials Arena